Related Experiment Video
Updated: Feb 27, 2026
09:06
Intra-lymph Node Injection of Biodegradable Polymer Particles
Published on: January 2, 2014
15.2K
Silica Nanoparticle as a Lymph Node Targeting Platform for Vaccine Delivery
Myunggi An1, Meng Li1, Jingchao Xi1
1Department of Chemical Engineering and Materials Science, Wayne State University , Detroit, Michigan 48202, United States.
ACS Applied Materials & Interfaces
|June 23, 2017
Summary
Silica nanoparticles (SiNPs) loaded with antigens and toll-like receptor 9 (TLR-9) agonists enhance vaccine responses. These SiNPs target antigen-presenting cells, boosting immunity while reducing systemic side effects for safer vaccine development.
Area of Science:
- Nanotechnology in vaccinology
- Immunology and immunotherapy
- Biomaterials and drug delivery
Background:
- Subunit vaccines require effective delivery systems to enhance immunogenicity.
- Nanoparticles offer a promising platform for vaccine development, but efficient targeting of antigen-presenting cells remains a challenge.
- Toll-like receptor 9 (TLR-9) agonists can boost immune responses but often cause systemic toxicities.
Purpose of the Study:
- To design and evaluate silica nanoparticles (SiNPs) co-loaded with antigen and a TLR-9 agonist for enhanced vaccine efficacy and safety.
- To investigate the targeting ability of these SiNPs to antigen-presenting cells in vivo.
- To assess the systemic toxicity profile of the SiNP-based vaccine compared to conventional TLR-9 agonists.
Main Methods:
- Development of silica nanoparticles (SiNPs) co-encapsulating an antigen and a TLR-9 agonist.
- In vivo studies in a murine model to assess nanoparticle accumulation in draining lymph nodes and antigen-presenting cells.
- Evaluation of antigen-specific B and T cell responses, antitumoral immunity, and systemic cytokine production and splenomegaly.
Main Results:
- SiNPs efficiently accumulated in antigen-presenting cells within draining lymph nodes after injection.
- SiNP-delivered vaccines induced significantly enhanced antigen-specific B and T cell responses and protective antitumoral immunity.
- SiNP vaccines markedly reduced systemic proinflammatory cytokines and completely abrogated splenomegaly, mitigating key toxicities of TLR-9 agonists.
Conclusions:
- Structure-optimized silica nanocarriers serve as an effective and safe platform for targeted delivery of subunit vaccines.
- Co-loading antigen and TLR-9 agonist onto SiNPs enhances vaccine efficacy and reduces associated systemic toxicities.
- This approach holds significant potential for advancing the clinical application of subunit vaccines and TLR-9 agonists.
